BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18522550)

  • 1. Combined heart and kidney transplantation in a patient with Fabry disease in the enzyme replacement therapy era.
    Karras A; De Lentdecker P; Delahousse M; Debauchez M; Tricot L; Pastural M; Bruneval P; Zemoura L; Duong Van Huyen JP; Lidove O
    Am J Transplant; 2008 Jun; 8(6):1345-8. PubMed ID: 18522550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Combined Heart and Kidney Transplantation in Patient With Fabry's Disease: A Case Report.
    Rajagopalan N; Dennis DR; O'Connor W
    Transplant Proc; 2019 Nov; 51(9):3171-3173. PubMed ID: 31371217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
    Cybulla M; Kurschat C; West M; Nicholls K; Torras J; Sunder-Plassmann G; Feriozzi S
    J Nephrol; 2013; 26(4):645-51. PubMed ID: 23023720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
    Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
    Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal transplantation in patients with Fabry disease.
    Sessa A; Meroni M; Battini G; Maglio A; Nebuloni M; Tosoni A; Panichi V; Bertagnolio B
    Nephron; 2002 Jun; 91(2):348-51. PubMed ID: 12053080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
    Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
    Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney transplantation in patients with Fabry disease.
    Cybulla M; Walter KN; Schwarting A; Divito R; Feriozzi S; Sunder-Plassmann G;
    Transpl Int; 2009 Apr; 22(4):475-81. PubMed ID: 19207191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Atrioventricular Block After Kidney Transplantation in a Patient With Fabry Disease Receiving Enzyme Replacement Therapy: A Case Report.
    Shin DW; Cho JY; Bae EH; Ma SK; Kim SW; Kim CS
    Transplant Proc; 2022; 54(1):107-111. PubMed ID: 34974891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal transplantation between siblings with unrecognized Fabry disease.
    Taneda S; Honda K; Nakajima I; Huchinoue S; Oda H
    Transplant Proc; 2013; 45(1):115-8. PubMed ID: 23375284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
    Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
    Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
    Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
    G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Management of Fabry Disease in High-Risk Renal Disease Patients in Taiwan: A Single Center Study.
    Shih CY; You ZH; Tsai SF; Wu MJ; Yu TM; Chuang YW; Chen CH
    Transplant Proc; 2023 May; 55(4):788-791. PubMed ID: 37230899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.
    Pastores GM; Boyd E; Crandall K; Whelan A; Piersall L; Barnett N
    Nephrol Dial Transplant; 2007 Jul; 22(7):1920-5. PubMed ID: 17395657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.